Neuraxis, Inc. (NRXS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Neuraxis, Inc. is a growth-stage medical device company specializing in neuromodulation therapies. Its primary revenue-generating product is the IB-STIM device for functional abdominal pain in children. The company also recently launched the RED (Rectal Expulsion Device) for adults. On July 1, 2025, the company terminated its license agreement with Masimo Corporation regarding the NSS-2 Bridge device, recapturing the trademark and patent applications for $200,000.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $811,414 | $666,625 | $2,601,155 | $1,924,760 |
| Gross Profit | $675,927 | $569,575 | $2,179,890 | $1,667,811 |
| Gross Margin | 83.3% | 85.4% | 83.8% | 86.7% |
| Operating Loss | $(2,100,085) | $(1,651,273) | $(6,113,040) | $(5,690,225) |
| Net Loss | $(2,122,796) | $(1,755,234) | $(6,091,898) | $(6,793,596) |
| Cash and Equivalents | $4,377,109 (as of Sept 30, 2025) | |||
| Working Capital | $1,840,599 (as of Sept 30, 2025) | |||
| Notes Payable (Current) | $195,658 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.7% quarter-over-quarter and 35.1% year-to-date, driven by volume growth in the IB-STIM device and the launch of the RED device. However, gross margin declined slightly due to higher discounting for patients without insurance and expired RED inventory.
- Expense Increases: Selling expenses surged 125.3% QoQ due to higher commissions, new headcount, and marketing spend targeting the upcoming Category I CPT code effective January 1, 2026. General and Administrative (G&A) expenses increased 7.2% QoQ, partially due to a one-time lawsuit settlement charge.
- Net Loss Improvement (YTD): While the Q3 net loss increased, the YTD net loss decreased by 10.3% compared to the prior year, primarily due to the absence of one-time non-recurring settlements and debt discount amortization charges that occurred in 2024.
- Capital Structure: The company raised approximately $5.0 million in May 2025 through the issuance of common stock and exercised warrants, significantly bolstering cash reserves.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Future operations depend on securing insurance coverage adoption and raising additional capital.
- Strategic Focus: The primary driver for future revenue is the adoption of insurance coverage for the IB-STIM device, specifically the new Category I CPT code effective January 1, 2026.
- Legal Contingencies:
- Settled Litigation: A $750,000 settlement was reached in May 2025 regarding a 2019 lawsuit (Bhambhani et al.). Payments begin in January 2026. A charge of $630,568 was recorded YTD 2025.
- Patent Dispute: An unresolved claim by Dr. Arturo Taca asserts an interest in a company patent valued at $2,000,000. The company intends to defend vigorously.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including ineffective approval processes and segregation of duties. Remediation efforts are ongoing.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $4.38M cash balance against the ~$4.5M operating cash burn observed in the first nine months of 2025.
- Insurance Adoption: Confirm progress on commercial insurance carrier adoption for the IB-STIM device, which is critical for the January 2026 CPT code rollout.
- Settlement Payments: Monitor cash outflows starting January 2026 for the $750,000 litigation settlement.
- Internal Control Remediation: Review subsequent filings for evidence of remediated material weaknesses in financial reporting controls.
- Dilution Risk: Assess the impact of potential future equity offerings required to fund operations given the "substantial doubt" going concern warning.